Search
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is...
Moderate to Severe Chronic Plaque Psoriasis
go.drugbank.com/conditions/DBCOND0032024Non-infectious Intermediate, Posterior and Panuveitis
go.drugbank.com/conditions/DBCOND0092758Drugs: AdalimumabCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigationalCertolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacin...
Isopropyl alcohol
go.drugbank.com/drugs/DB02325ApprovedInvestigationalAn isomer of 1-propanol. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
Mixtures: Adalimumab, AdalimumabBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Moderate to Severe Rheumatoid Arthritis
go.drugbank.com/conditions/DBCOND0065339Moderately to Severely Active Crohn's Disease
go.drugbank.com/conditions/DBCOND0093405Pyoderma Gangrenosum
go.drugbank.com/conditions/DBCOND0005724